Pharma news

• 

  3 October 2025

  Roche Board Update: Claudia Süssmuth Dyckerhoff Steps Down

  Dr. Claudia Süssmuth Dyckerhoff will not seek re-election to Roche's Board in 2026, opting for a board role at another healthcare company. She has been a board member since 2016.
• 

  1 October 2025

  IFF Achieves ISO/IEC 27001 Certification for Data Security

  IFF's ISO/IEC 27001:2022 certification enhances data security, supporting customer trust and compliance in regulated industries.
• 

  1 October 2025

  LyondellBasell Expands Purell Polymers in North America

  Purell healthcare polymers expand in North America, enhancing regulatory compliance, quality, and supply predictability for medical applications.
• 

  1 October 2025

  Mitsui Chemicals Acquires Nippon Aluminum Alkyls

  NAA, a producer of organometallic compounds, is now a wholly owned subsidiary, enhancing Mitsui's focus on catalysts for polyolefins and sustainable chemicals. Impact on performance is minimal.
• 

  30 September 2025

  Merck's WINREVAIR Reduces PAH Clinical Worsening Risk by 76% in Phase 3 Trial

  WINREVAIR, when started within a year of PAH diagnosis, significantly lowers clinical worsening risk. Safety profile aligns with previous trials. Results shared at ERS 2025 and published in NEJM.
• 

  30 September 2025

  Roche's New Troponin T Test Enhances Heart Attack Diagnosis Accuracy

  The new test improves heart attack diagnosis speed and accuracy, aiding emergency care efficiency and patient outcomes, validated by a global study of over 13,000 participants.

• 

  29 September 2025

  Genmab Acquires Merus for $8 Billion, Boosting Pipeline

  Acquisition adds petosemtamab to Genmab's portfolio, aiming for 2027 launch. Expected to enhance growth and EBITDA by 2029.
• 

  29 September 2025

  Novo Nordisk Resubmits Awiqli® to FDA for Once-Weekly Basal Insulin Approval

  Awiqli® resubmitted to FDA for approval as first once-weekly basal insulin for type 2 diabetes, based on ONWARDS trial results.
• 

  29 September 2025

  Novo Nordisk Submits BLA for Hemophilia A Treatment Mim8 to FDA

  Mim8, a bispecific antibody for hemophilia A, offers flexible dosing and is under FDA review. It aims to improve clotting and reduce bleeding episodes.
• 

  25 September 2025

  Aptar Pharma Opens New R&D Center in France

  The new center enhances R&D capabilities, supports innovation, and integrates sustainable features, focusing on advanced drug delivery solutions.
• 

  24 September 2025

  Roche Unveils New Data on OCREVUS and Fenebrutinib at ECTRIMS 2025

  OCREVUS shows reduced disability progression in MS patients; fenebrutinib demonstrates near-complete disease activity suppression over two years.
• 

  23 September 2025

  Merck and Siemens Partner to Boost AI in Drug Development

  The partnership aims to enhance drug discovery with digital solutions, integrating AI and data to streamline processes and accelerate scientific progress.
• 

  22 September 2025

  Evonik Introduces MaxiPure® Polysorbate 80 for Injectable Drugs

  MaxiPure® Polysorbate 80 offers ultra-high purity for injectable drugs, enhancing protein stability and solubilization, while ensuring regulatory compliance and formulation reliability.
• 

  22 September 2025

  Nemera Selects Bormed™ PP for Scalable Pen Injector in Chronic Care

  Nemera's new pen injector uses Bormed™ PP for safety, sustainability, and high-volume production, reducing carbon footprint by 20% and enhancing usability with color-coded features.
• 

  22 September 2025

  Roche's Giredestrant Boosts Progression-Free Survival in ER-Positive Breast Cancer

  Phase III trial shows giredestrant plus everolimus improves progression-free survival in ER-positive breast cancer, with no new safety concerns.
• 

  19 September 2025

  Roche's Lunsumio Subcutaneous Formulation Recommended for EU Approval

  Lunsumio SC offers faster administration and high response rates for relapsed follicular lymphoma, with low cytokine release syndrome risk, pending EU approval.
• 

  19 September 2025

  FDA Approves Merck's Subcutaneous KEYTRUDA QLEX for Solid Tumors

  KEYTRUDA QLEX, a subcutaneous immune checkpoint inhibitor, offers comparable efficacy to IV KEYTRUDA in treating metastatic NSCLC, with administration possible in one minute by healthcare providers.
• 

  19 September 2025

  Merck's ENFLONSIA™ Recommended by EU CHMP for RSV Prevention in Infants

  ENFLONSIA™ awaits EU approval for infant RSV prevention, offering a single-dose option for all weights. Backed by Phase 2b/3 and Phase 3 trials, decision expected by year-end.
• 

  19 September 2025

  Merck Gains EU CHMP Support for KEYTRUDA SC and New Head and Neck Cancer Use

  CHMP backs KEYTRUDA SC for all EU adult indications and a new use in LA-HNSCC. Awaiting European Commission's final decision.
• 

  18 September 2025

  Roche to Acquire 89bio and Its Phase 3 FGF21 Analog for MASH Treatment

  Roche enhances its CVRM portfolio with 89bio's pegozafermin, targeting MASH. The deal is valued up to $3.5 billion, with potential milestone payments. Completion expected Q4 2025.
• 

  18 September 2025

  Aptar Pharma's Unidose System Delivers First FDA-Approved Intranasal Diuretic Enbumyst

  Enbumyst™, an intranasal diuretic, offers a faster, self-administered alternative for edema treatment, using Aptar's Unidose System for effective nasal drug delivery.
• 

  18 September 2025

  Novo Nordisk: Ozempic® Cuts Heart Attack, Stroke, and Death Risk by 23% vs. Dulaglutide

  Ozempic® shows 26% lower death risk and 25% reduced risk of major cardiovascular events in older diabetes patients compared to dulaglutide in a real-world study.
• 

  18 September 2025

  BENEO Gains Thai FDA Approval for Prebiotic Claim

  Thai FDA approves chicory root fibre Orafti® Inulin for prebiotic claims, aligning with rising consumer interest in digestive health.
• 

  17 September 2025

  WuXi Biologics Gains GMP Certification for Three Facilities from Turkey's TITCK

  Three WuXi facilities passed TITCK's inspection, reinforcing their global quality standards and expanding into the Turkish market.
• 

  17 September 2025

  Novo Nordisk's Oral Semaglutide Achieves 16.6% Weight Loss in Obesity Study

  Oral semaglutide 25 mg shows significant weight loss and improved physical activity in a 64-week trial, with mild to moderate side effects, pending FDA approval.
• 

  16 September 2025

  Evonik Introduces Clinical-Grade VECOLLAN® Collagen

  VECOLLAN® is now available for clinical trials, offering a non-animal collagen alternative for medical devices, enhancing safety and performance through sustainable production.
• 

  16 September 2025

  Novo Nordisk Advances Cagrilintide to Phase 3 Clinical Program After Positive Results

  Cagrilintide shows significant weight loss and tolerability in trials, prompting further study in the RENEW phase 3 program for obesity treatment.
• 

  16 September 2025

  Takeda Partners with VELA for Wind-Powered Trimaran Shipping

  VELA's wind-powered trimaran will cut emissions by up to 99% for pharma shipping, ensuring cold-chain integrity and faster transatlantic delivery without invasive species transfer.
• 

  15 September 2025

  Novo Nordisk's Wegovy® Reduces Food Noise, Enhances Mental Well-being

  Wegovy® users reported a 46% drop in constant food thoughts, improved mental health (64%), and healthier habits (80%) in a real-world survey.
• 

  15 September 2025

  Novo Nordisk's Oral Semaglutide Approved in EU for Cardiovascular Benefits

  EMA approves Rybelsus® label update for cardiovascular benefits in type 2 diabetes. SOUL trial shows reduced hospitalizations and consistent benefits across BMI and weight.